Helixgate

Helixgate

Uncategorized

STAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill

Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in a notoriously deadly and intractable malignancy. 

Patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy.

It’s “very impressive,” said Benjamin Weinberg, an associate professor of medicine at Georgetown University who was not involved in the study, in an email.

Continue to STAT+ to read the full story…

Read More

Published

on

Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in a notoriously deadly and intractable malignancy. 

Patients who took the daily pill, called daraxonrasib, lived a median of 13.2 months, compared to 6.7 months for patients who received chemotherapy.

It’s “very impressive,” said Benjamin Weinberg, an associate professor of medicine at Georgetown University who was not involved in the study, in an email.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Published

on

After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.​ ​Read More

Continue Reading

Uncategorized

Chile offers new data on food warning label efficacy

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Continue Reading

Uncategorized

Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

Published

on

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

Continue Reading
Advertisement

Trending